Tumor necrosis factor inhibitors and infection complications - PubMed (original) (raw)

Review

Tumor necrosis factor inhibitors and infection complications

Monica Crawford et al. Curr Rheumatol Rep. 2008 Oct.

Abstract

Rheumatoid arthritis patients are at heightened risk for infections because of intrinsic disease severity with associated inflammation, comorbid illnesses, and use of glucocorticoids and various immunosuppressives. Although several studies have reported up to a twofold increase in risk of serious infections in RA patients treated with anti-tumor necrosis factor-alpha agents, results from other studies have been conflicting. Comparing results from different studies is challenging because of differences in patient populations, heterogeneous prevalence of comorbidities, and differing patterns of concomitant medication use. Based on available evidence, an excess risk for infection occurs early after initiation of tumor necrosis factor-alpha inhibitor therapy. Additionally, special circumstances such as surgical procedures may increase infection risk. The appropriate use of biologics in the perioperative setting remains empiric at best.

PubMed Disclaimer

Figures

Figure 1

Time-dependent relationship in the risk for serious infections associated with etanercept (ETN) and infliximab (INF).

Cited by

Tumor necrosis factor regulates leukocyte recruitment but not bacterial persistence during Staphylococcus aureus craniotomy infection.
Van Roy Z, Kielian T. Van Roy Z, et al. J Neuroinflammation. 2024 Jul 23;21(1):179. doi: 10.1186/s12974-024-03174-9. J Neuroinflammation. 2024. PMID: 39044282 Free PMC article.
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.
Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN. Hammell DC, et al. Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30. Eur J Pain. 2016. PMID: 26517407 Free PMC article.
Magnetic resonance imaging of the sacroiliac joints in SpA: with or without intravenous contrast media? A preliminary report.
Gentili F, Cantarini L, Fabbroni M, Nigri A, Mazzei FG, Frediani B, Galeazzi M, Volterrani L, Mazzei MA. Gentili F, et al. Radiol Med. 2019 Nov;124(11):1142-1150. doi: 10.1007/s11547-019-01016-w. Epub 2019 Mar 13. Radiol Med. 2019. PMID: 30868439
Tumor necrosis factor blockade and the risk of viral infection.
Kim SY, Solomon DH. Kim SY, et al. Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9. Nat Rev Rheumatol. 2010. PMID: 20142812 Free PMC article. Review.
Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice.
Yokoyama W, Kohsaka H, Kaneko K, Walters M, Takayasu A, Fukuda S, Miyabe C, Miyabe Y, Love PE, Nakamoto N, Kanai T, Watanabe-Imai K, Charvat TT, Penfold ME, Jaen J, Schall TJ, Harigai M, Miyasaka N, Nanki T. Yokoyama W, et al. Arthritis Res Ther. 2014 Sep 24;16(5):445. doi: 10.1186/s13075-014-0445-9. Arthritis Res Ther. 2014. PMID: 25248373 Free PMC article.

References

1. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56:2563–2569. - PMC - PubMed
1. Kato K, Minagawa T, Kato K, et al. Human tumor necrosis factor increases the resistance against Listeria infection in mice. Med Microbiol Immunol. 1989;178:337–346. - PubMed
1. Mastroeni P, Villarreal-Ramos B, Hormaeche CE. Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. Microb Pathog. 1993;14:473–480. - PubMed
1. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–2300. - PubMed
1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293. - PubMed

Tumor necrosis factor inhibitors and infection complications - PubMed (original) (raw)